Washington University in St. Louis (WU)
My laboratory research is focused on deciphering mechanisms of dysregulated signaling in myeloproliferative neoplasms (MPNs). We recently identified novel mutations in the adapter protein LNK, a negative regulator of JAK-STAT signaling, in MPN patients, and ongoing work is aimed at characterizing the functional impact of these LNK mutations on MPN pathogenesis. We utilize phospho-specific flow cytometry to evaluate signaling in MPN patient samples, and are developing next-generation mass cytometry technologies to facilitate high parameter, phospho-proteomic approaches to characterize aberrant signaling at the network level. The ultimate goal is to translate this work into improved therapies for MPN patients.